Clinical Trials
53 trialsTesting the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer
National Cancer Institute (NCI)
Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma
National Cancer Institute (NCI)
Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
National Cancer Institute (NCI)
Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer
National Cancer Institute (NCI)
Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies
National Institutes of Health Clinical Center (CC)
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
National Cancer Institute (NCI)
Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer
National Cancer Institute (NCI)
Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer
National Cancer Institute (NCI)
Onalespib in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin
National Cancer Institute (NCI)
Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers
National Cancer Institute (NCI)
Methoxyamine Hydrochloride, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Cisplatin, Intensity-Modulated Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma
National Cancer Institute (NCI)
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors
National Institutes of Health Clinical Center (CC)
Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System
National Cancer Institute (NCI)
Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Chemoradiation Therapy and Ipilimumab in Treating Patients With Stages IB2-IIB or IIIB-IVA Cervical Cancer
National Cancer Institute (NCI)
Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer
National Institutes of Health Clinical Center (CC)
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
National Cancer Institute (NCI)
A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers
National Institutes of Health Clinical Center (CC)
SS1(dsFV)PE38 Plus Pemetrexed and Cisplatin to Treat Malignant Pleural Mesothelioma
National Institutes of Health Clinical Center (CC)
AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers
National Institutes of Health Clinical Center (CC)
Eribulin Mesylate and Cisplatin in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
R-(-)-Gossypol Acetic Acid, Cisplatin, and Etoposide in Treating Patients With Advanced Solid Tumors or Extensive Stage Small Cell Lung Cancer
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors
National Cancer Institute (NCI)
SU5416 Combined With Gemcitabine and Cisplatin in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Edotecarin and Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors
National Cancer Institute (NCI)
Erlotinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Mouth or Throat Cancer
National Cancer Institute (NCI)
Hydroxyurea Plus Combination Chemotherapy in Patients With Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phosphorus-32 Plus Radiation Therapy and Chemotherapy in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Cisplatin Plus Bryostatin 1 in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
3-AP Plus Cisplatin and Paclitaxel in Treating Patients With Advanced or Metastatic Cancer
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
Gemcitabine and Cisplatin in Treating Patients With Metastatic or Recurrent Solid Tumors
National Cancer Institute (NCI)
ONYX-015 With Cisplatin and Fluorouracil in Treating Patients With Advanced Head and Neck Cancer
National Cancer Institute (NCI)
7-hydroxystaurosporine and Cisplatin in Treating Patients With Advanced Malignant Solid Tumors
National Cancer Institute (NCI)
Irinotecan and Cisplatin With or Without Amifostine in Treating Children With Solid Tumors That Have Not Responded to Previous Therapy
National Cancer Institute (NCI)
Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Tirapazamine, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer
National Cancer Institute (NCI)
Tanespimycin, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
Rebeccamycin Analog and Cisplatin With or Without Filgrastim in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
SU5416, Irinotecan, and Cisplatin in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Gefitinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck Cancer
National Cancer Institute (NCI)
Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer
National Cancer Institute (NCI)
Phase I Study of Intravenous Triapine (IND # 68338) in Combination With Pelvic Radiation Therapy With or Without Weekly Intravenous Cisplatin Chemotherapy for Locally Advanced Cervical, Vaginal, or Pelvic Gynecologic Malignancies
National Cancer Institute (NCI)
Bortezomib, Cetuximab, and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage IV Head and Neck Cancer
National Institutes of Health Clinical Center (CC)
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Radiolabeled Monoclonal Antibody, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory B-Cell Cancer
National Cancer Institute (NCI)